Agilent Technologies

Revenue and FCF are fairly predictable over the long term. The business is diversified across research and clinical markets globally, providing some insulation.

For instance, in Q3FY2024 the CrossLab services segment grew 5% (driven by recurring consumables and maintenance contracts) even as the Life Sciences instrumentation segment fell ~8% due to biotech funding downturns). This mix of stable services and capital equipment yields reasonably steady cash flow.

Agilent also benefits from secular trends in biotech and pharma R&D – the CEO notes improved biotech demand ahead, helped by possible Fed rate cuts. Overall, growth is modest (1-5% recently) but reliable, giving it a solid predictability score (70).

The revenue base is not extremely cyclical (unlike manufacturing or travel) and is globally diversified (mostly US/EU).